Abstract
Adult T-cell leukemia/lymphoma (ATL) cells are generally CD4+, CD8- and CCR4+. A 76-year-old man was diagnosed with a rare case of CD4-/CD8+ ATL in 2013. He was initially treated with the THP-COP regimen. The number of ATL cells in lymph nodes and peripheral blood (PB) and the level of soluble interleukin-2 receptor (sIL2R) were decreased initially after chemotherapy but increased within 3 months and hypercalcemia appeared. Thus, the patient was diagnosed with ATL progression. Since CCR4 expression in CD4-/CD8+ ATL cells was confirmed by flow cytometry, the patient was treated with the newly developed CCR4 antibody mogamulizumab. Treatment significantly eradicated ATL cells in PB. To our knowledge, this is the first case of CD4- ATL treated with mogamulizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
